---
title: Competitive Landscape Analyst - Comprehensive Test Suite
date: 2025-11-23
purpose: Systematic testing of all competitive-landscape-analyst capabilities
agent: competitive-landscape-analyst
test_levels: 4 (Basic → Strategic Synthesis)
data_sources_researched:
  - Yahoo Finance News (pharmaceutical industry trends)
  - Current market events (Eli Lilly $1T cap, ADC trend, M&A activity)
current_events_grounding:
  - Eli Lilly reaches $1 trillion market cap (first pharma, driven by obesity drugs)
  - Big Pharma M&A activity ~$150B in 2025
  - Antibody-drug conjugates (ADCs) emerging as "smart bombs" for cancer
  - Pfizer KEYTRUDA + PADCEV combo approved for bladder cancer
  - Bristol Myers Squibb cardiovascular setback (Librexia ACS study)
  - China biotech surge continuing in 2025
  - Obesity drug deals driving landmark valuations
capabilities_tested: 12 core capability areas
total_queries: 40+
complexity_progression: Simple single-focus → Complex multi-domain synthesis
---

# Competitive Landscape Analyst - Comprehensive Test Suite

## Executive Summary

This document provides a systematic test suite for the **competitive-landscape-analyst** strategic agent, designed to validate all 12 core capability areas through 40+ queries organized in 4 complexity levels. Test queries are grounded in current pharmaceutical news (November 2025) including Eli Lilly's $1 trillion market cap milestone, antibody-drug conjugate trends, and major M&A activity.

**Test Philosophy**: Progress from simple, focused queries requiring minimal data to complex strategic synthesis requiring multi-domain data collection and deep analysis.

**Current Events Context**:
- **Eli Lilly**: First pharma to hit $1T market cap (obesity drug portfolio: tirzepatide/Mounjaro/Zepbound)
- **ADCs**: "Fighting Cancer With 'Smart Bombs'" - antibody-drug conjugates gaining momentum
- **M&A**: Big Pharma spending ~$150B on deals in 2025
- **Approvals**: Pfizer's KEYTRUDA + PADCEV combo approved for bladder cancer
- **Setbacks**: Bristol Myers Squibb's Librexia ACS study failure
- **Geography**: China biotech surge driving global interest

---

## Agent Invocation Pattern

**ALL queries in this test suite use explicit agent invocation**:

```
@agent-competitive-landscape-analyst "Query here"
```

**Why explicit invocation?**
- competitive-landscape-analyst is a strategic agent (Layer 3)
- Requires metadata-driven data orchestration
- Main agent must read agent YAML frontmatter
- Main agent collects data before invoking strategic agent

**Expected Flow**:
1. User types: `@agent-competitive-landscape-analyst "Analyze obesity drugs"`
2. Main agent reads: `.claude/agents/competitive-landscape-analyst.md` (metadata)
3. Main agent infers: `therapeutic_area = "obesity drugs"`
4. Main agent applies patterns: `get_obesity_drugs_trials`, `get_obesity_drugs_fda_drugs`
5. Main agent uses strategy system to REUSE/ADAPT/CREATE skills
6. Main agent executes skills and collects data
7. Main agent invokes strategic agent with collected data
8. Strategic agent returns analysis
9. Main agent saves report to `reports/competitive-landscape/`

---

## Test Suite Organization

### Complexity Levels

**Level 1: Basic Single-Focus Queries** (5-10 min analysis)
- Single therapeutic area or company
- Minimal data requirements (1-2 skills)
- Focused on recent news events
- Output: 1000-1500 word summary
- Tests: Pipeline tracking, basic competitive positioning

**Level 2: Intermediate Dual-Source Queries** (10-20 min analysis)
- Therapeutic area with clinical + regulatory data
- Moderate data requirements (2-4 skills)
- Basic competitive positioning
- Output: 2000-3000 word analysis
- Tests: Clinical trial monitoring, financial analysis, strategic synthesis

**Level 3: Advanced Multi-Domain Queries** (20-40 min analysis)
- Multiple data sources (trials, FDA, patents, financial)
- Complex data requirements (4-6 skills)
- Deep competitive intelligence
- Output: 3000-5000 word report
- Tests: Partnership intelligence, risk assessment, analytical frameworks

**Level 4: Strategic Synthesis Queries** (40-60 min analysis)
- Comprehensive multi-domain analysis
- Extensive data requirements (6+ skills)
- Full competitive landscape with recommendations
- Output: 4000-6000 word strategic report
- Tests: All capabilities, action planning, board-ready deliverables

### Capability Coverage Matrix

Each query tests specific capabilities from the agent definition:

| Capability Area | Level 1 | Level 2 | Level 3 | Level 4 |
|----------------|---------|---------|---------|---------|
| 1. Pipeline Intelligence & Tracking | ✓✓✓ | ✓✓✓ | ✓✓✓ | ✓✓✓ |
| 2. Clinical Trial Monitoring | ✓✓ | ✓✓✓ | ✓✓✓ | ✓✓✓ |
| 3. Financial & Investment Analysis | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |
| 4. Strategic Intelligence Synthesis | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |
| 5. Data Collection & Source Mgmt | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |
| 6. Analytical Frameworks | - | ✓ | ✓✓✓ | ✓✓✓ |
| 7. Reporting & Communication | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |
| 8. Technology & Automation | - | ✓ | ✓✓ | ✓✓✓ |
| 9. Therapeutic Area Specialization | ✓✓ | ✓✓✓ | ✓✓✓ | ✓✓✓ |
| 10. Partnership & Deal Intelligence | - | ✓ | ✓✓✓ | ✓✓✓ |
| 11. Risk Assessment & Early Warning | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |
| 12. Action Planning & Recommendations | ✓ | ✓✓ | ✓✓✓ | ✓✓✓ |

✓ = Basic coverage, ✓✓ = Moderate coverage, ✓✓✓ = Comprehensive coverage

---

## LEVEL 1: Basic Single-Focus Queries

**Purpose**: Test core pipeline tracking and basic competitive positioning with minimal data requirements. Queries grounded in recent news events.

**Expected Runtime**: 5-10 minutes per query
**Expected Output**: 1000-1500 word summary
**Data Requirements**: 1-2 skills (trials OR FDA drugs OR financial)

---

### Query L1.1: Eli Lilly $1 Trillion Market Cap Event

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze Eli Lilly's path to becoming the first $1 trillion pharma company. What drove this valuation milestone?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (Single company, recent event)

**Current News Context**:
- Eli Lilly market cap hit $1 trillion (Nov 2025)
- First pharmaceutical company to reach this milestone
- Stock gained $400 billion in just 3 months
- Driven primarily by obesity drug portfolio (tirzepatide/Mounjaro/Zepbound)

**Data Requirements**:
- Company financial data: Stock performance, market cap history (via `financials_mcp`)
- Approved drugs: FDA approvals for obesity drugs (via `fda_mcp`)
- Clinical trials: Late-stage obesity pipeline (via `ct_gov_mcp`)

**Skills Likely Needed**:
```
get_eli_lilly_stock_data (financials_mcp)
get_glp1_obesity_fda_drugs (fda_mcp)
get_eli_lilly_obesity_trials (ct_gov_mcp)
```

**Expected Analysis Output**:
1. **Market Cap Milestone Context**:
   - Timeline to $1T (vs. tech companies)
   - Stock price acceleration ($400B in 3 months)
   - Valuation metrics (P/E ratio, revenue multiples)

2. **Portfolio Drivers**:
   - Obesity drugs: Mounjaro (diabetes), Zepbound (obesity)
   - Tirzepatide mechanism (GLP-1/GIP dual agonist)
   - Market dominance vs. Novo Nordisk

3. **Pipeline Strength**:
   - Oral GLP-1 programs (orforglipron)
   - Next-generation obesity therapies
   - Combination approaches

4. **Strategic Implications**:
   - Sustainability of valuation (patent cliffs, competition)
   - R&D reinvestment opportunities
   - Acquisition capacity with elevated valuation

**Capabilities Tested**:
- ✓ Financial & Investment Analysis
- ✓ Pipeline Intelligence & Tracking
- ✓ Strategic Intelligence Synthesis
- ✓ Reporting & Communication
- ✓ Therapeutic Area Specialization (metabolic)

**Business Value**: Understanding what drives pharma mega-cap valuations, obesity market dynamics, competitive positioning strategy

**Success Criteria**:
- Quantitative analysis of market cap drivers
- Clear attribution to specific products/pipeline
- Forward-looking sustainability assessment
- Actionable insights for investors/competitors

---

### Query L1.2: Bristol Myers Squibb Cardiovascular Setback

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the impact of Bristol Myers Squibb's Librexia ACS study failure on their cardiovascular portfolio"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (Single company, single setback event)

**Current News Context**:
- Bristol Myers Squibb's Librexia failed ACS (acute coronary syndrome) study
- Setback to cardiovascular portfolio expansion
- Stock impact and analyst downgrades
- Company already facing patent cliffs on major drugs

**Data Requirements**:
- Clinical trials: BMY cardiovascular pipeline (via `ct_gov_mcp`)
- FDA drugs: BMY approved cardiovascular drugs (via `fda_mcp`)
- Financial: Stock reaction, analyst ratings (via `financials_mcp`)

**Skills Likely Needed**:
```
get_bristol_myers_squibb_cardiovascular_trials (ct_gov_mcp)
get_bristol_myers_squibb_cardiovascular_fda_drugs (fda_mcp)
get_bristol_myers_squibb_stock_data (financials_mcp)
```

**Expected Analysis Output**:
1. **Study Failure Context**:
   - Librexia mechanism and ACS indication
   - Study design and endpoints
   - Reasons for failure (efficacy, safety, both?)

2. **Portfolio Impact Assessment**:
   - Remaining cardiovascular assets
   - Pipeline depth post-failure
   - Patent cliff exposure (Eliquis LOE approaching)

3. **Competitive Position**:
   - Competitors in ACS space
   - Market share implications
   - Strategic alternatives

4. **Risk Mitigation Recommendations**:
   - Portfolio diversification needs
   - BD&L opportunities in cardiovascular
   - Investor communication strategy

**Capabilities Tested**:
- ✓ Risk Assessment & Early Warning
- ✓ Pipeline Intelligence & Tracking
- ✓ Financial & Investment Analysis
- ✓ Strategic Intelligence Synthesis
- ✓ Action Planning & Recommendations

**Business Value**: Understanding pipeline failure impact, risk assessment, portfolio gap analysis

**Success Criteria**:
- Clear quantification of portfolio impact
- Competitive context for setback
- Actionable mitigation strategies
- Investor perspective included

---

### Query L1.3: Antibody-Drug Conjugate (ADC) Momentum

**User Input**:
```
@agent-competitive-landscape-analyst "Why are antibody-drug conjugates (ADCs) being called 'smart bombs' for cancer? Analyze the current competitive landscape."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (Single modality, emerging trend)

**Current News Context**:
- "Fighting Cancer With 'Smart Bombs'" headline (Investor's Business Daily)
- ADCs gaining Wall Street attention
- Multiple recent FDA approvals
- Technology platform competition intensifying

**Data Requirements**:
- FDA drugs: Approved ADCs and their targets (via `fda_mcp`)
- Clinical trials: ADC trials across cancer types (via `ct_gov_mcp`)
- Patents: ADC technology platforms (via `uspto_patents_mcp`) [optional]

**Skills Likely Needed**:
```
get_adc_approved_drugs (fda_mcp)
get_adc_trials (ct_gov_mcp)
```

**Expected Analysis Output**:
1. **ADC Technology Overview**:
   - Mechanism: antibody + linker + payload
   - "Smart bomb" concept (targeted delivery)
   - Advantages vs. traditional chemotherapy

2. **Approved ADC Landscape**:
   - Count of FDA-approved ADCs
   - Target antigens (HER2, CD19, BCMA, etc.)
   - Payload diversity (auristatin, maytansine, etc.)
   - Indication expansion (hematologic → solid tumors)

3. **Clinical Pipeline**:
   - Late-stage ADC programs
   - Novel targets being pursued
   - Combination strategies (ADC + checkpoint inhibitor)

4. **Competitive Intelligence**:
   - Leading companies (Daiichi Sankyo, AstraZeneca, Pfizer, Seagen)
   - Technology platforms (linker chemistry, site-specific conjugation)
   - Partnership landscape

**Capabilities Tested**:
- ✓ Pipeline Intelligence & Tracking
- ✓ Therapeutic Area Specialization (oncology)
- ✓ Strategic Intelligence Synthesis
- ✓ Technology platform assessment
- ✓ Reporting & Communication

**Business Value**: Understanding emerging modality trends, technology platform evaluation, investment opportunities

**Success Criteria**:
- Clear explanation of ADC technology advantage
- Comprehensive approved + pipeline landscape
- Identification of competitive leaders
- Assessment of remaining opportunities

---

### Query L1.4: Pfizer KEYTRUDA + PADCEV Combo Approval

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the competitive significance of Pfizer's KEYTRUDA + PADCEV combo approval for bladder cancer"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (Single approval event, recent news)

**Current News Context**:
- FDA approved KEYTRUDA (pembrolizumab) + PADCEV (enfortumab vedotin) combo
- Indication: Perioperative treatment for cisplatin-ineligible muscle-invasive bladder cancer
- Combination of checkpoint inhibitor + ADC
- Expands treatment options for hard-to-treat population

**Data Requirements**:
- FDA approval: KEYTRUDA + PADCEV details (via `fda_mcp`)
- Clinical trials: Bladder cancer combination trials (via `ct_gov_mcp`)
- Competitive landscape: Other bladder cancer therapies (via `fda_mcp`)

**Skills Likely Needed**:
```
get_bladder_cancer_fda_drugs (fda_mcp)
get_bladder_cancer_combination_trials (ct_gov_mcp)
get_keytruda_padcev_approval_data (fda_mcp)
```

**Expected Analysis Output**:
1. **Approval Context**:
   - Patient population (cisplatin-ineligible, muscle-invasive)
   - Perioperative setting (before/after surgery)
   - Clinical trial data supporting approval
   - Unmet medical need addressed

2. **Combination Strategy**:
   - KEYTRUDA mechanism (PD-1 checkpoint inhibitor)
   - PADCEV mechanism (ADC targeting Nectin-4)
   - Synergy rationale
   - Safety profile

3. **Competitive Landscape**:
   - Existing bladder cancer treatments
   - Other combination approaches in development
   - Market size and growth potential

4. **Strategic Implications**:
   - Pfizer's oncology portfolio strengthening
   - Combination therapy trend validation
   - Label expansion opportunities

**Capabilities Tested**:
- ✓ Pipeline Intelligence & Tracking
- ✓ Clinical Trial Monitoring
- ✓ Strategic Intelligence Synthesis
- ✓ Therapeutic Area Specialization (oncology)
- ✓ Combination therapy analysis

**Business Value**: Understanding combination therapy strategies, regulatory pathways, competitive differentiation

**Success Criteria**:
- Clear explanation of combination rationale
- Competitive positioning vs. existing therapies
- Market opportunity assessment
- Strategic implications for competitors

---

### Query L1.5: China Biotech Surge

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the China biotech surge in 2025. What are the key trends and implications for Western pharma?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (Geographic/market trend analysis)

**Current News Context**:
- "China biotech surge" identified as major 2025 trend
- Western pharma companies acquiring Chinese assets
- NMPA regulatory improvements
- Cost advantages for clinical trials
- Innovation in specific therapeutic areas

**Data Requirements**:
- Clinical trials: China vs. US trial distribution (via `ct_gov_mcp`)
- M&A activity: Western pharma acquiring Chinese biotech (via `sec_edgar_mcp`) [optional]
- Financial: Chinese biotech company valuations (via `financials_mcp`) [optional]

**Skills Likely Needed**:
```
get_china_oncology_trials (ct_gov_mcp)
get_us_china_trial_comparison (ct_gov_mcp)
```

**Expected Analysis Output**:
1. **China Biotech Growth Metrics**:
   - Clinical trial volume growth
   - Regulatory approval trends (NMPA)
   - Investment and funding activity
   - IPO activity (Hong Kong, NASDAQ)

2. **Innovation Hotspots**:
   - Therapeutic areas of strength (oncology, CAR-T)
   - Novel targets and mechanisms
   - Technology platforms (cell therapy, antibodies)

3. **Western Pharma Engagement**:
   - M&A activity (acquisitions, licensing deals)
   - Collaboration patterns
   - Market access strategies

4. **Strategic Implications**:
   - Competitive threat assessment
   - Partnership opportunities
   - Clinical trial geography strategy
   - IP and data sharing considerations

**Capabilities Tested**:
- ✓ Strategic Intelligence Synthesis
- ✓ Geographic market analysis
- ✓ Partnership & Deal Intelligence
- ✓ Risk Assessment & Early Warning
- ✓ Action Planning & Recommendations

**Business Value**: Understanding global competitive dynamics, partnership strategy, geographic expansion planning

**Success Criteria**:
- Quantitative assessment of China biotech growth
- Identification of therapeutic area strengths
- Clear strategic implications for Western pharma
- Actionable recommendations (partner, acquire, compete)

---

### Query L1.6: Big Pharma M&A Activity ($150B in 2025)

**User Input**:
```
@agent-competitive-landscape-analyst "Big Pharma has spent nearly $150 billion on M&A in 2025. What are the key drivers and which therapeutic areas are hottest?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Basic (M&A trend analysis)

**Current News Context**:
- Forbes headline: "Big Pharma Has Spent Nearly $150 Billion On M&A"
- Obesity drug deals driving high valuations
- Patent cliff pressures
- Technology platform acquisitions
- China biotech asset acquisitions

**Data Requirements**:
- M&A deals: SEC filings for major deals (via `sec_edgar_mcp`)
- Financial: Deal values and strategic rationale (via `financials_mcp`)
- [Optional] Pipeline analysis: Acquired assets (via `ct_gov_mcp`, `fda_mcp`)

**Skills Likely Needed**:
```
get_biotech_ma_deals_over_1b (sec_edgar_mcp)
get_pharma_stock_performance (financials_mcp)
```

**Expected Analysis Output**:
1. **M&A Activity Metrics**:
   - Total deal value ($150B)
   - Number of deals by size tier
   - Average premium paid
   - Deal structure trends (all-cash, stock, CVRs)

2. **Therapeutic Area Analysis**:
   - Which areas attracting most M&A (obesity, oncology, rare disease)
   - Rationale for each (market size, innovation, pipeline gaps)
   - Technology platforms being acquired

3. **Strategic Drivers**:
   - Patent cliff mitigation
   - Pipeline gaps filling
   - Technology platform acquisition
   - Geographic expansion (China assets)

4. **Competitive Implications**:
   - Which companies most active (Pfizer, Bristol Myers, etc.)
   - Consolidation trends
   - Remaining attractive targets
   - Valuation benchmarks

**Capabilities Tested**:
- ✓ Partnership & Deal Intelligence
- ✓ Financial & Investment Analysis
- ✓ Strategic Intelligence Synthesis
- ✓ Portfolio gap identification
- ✓ Action Planning & Recommendations

**Business Value**: Understanding M&A trends, valuation benchmarks, identifying acquisition targets

**Success Criteria**:
- Quantitative M&A activity summary
- Therapeutic area hotspot identification
- Strategic driver analysis
- Implications for future deals

---

## LEVEL 2: Intermediate Dual-Source Queries

**Purpose**: Test clinical trial monitoring + regulatory analysis with moderate data requirements. Requires synthesis across 2-4 data sources.

**Expected Runtime**: 10-20 minutes per query
**Expected Output**: 2000-3000 word analysis
**Data Requirements**: 2-4 skills (trials + FDA drugs + financial/patents)

---

### Query L2.1: Obesity Drug Market Competitive Dynamics

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the competitive dynamics in the obesity drug market. How sustainable is Eli Lilly's market cap given the pipeline competition?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Therapeutic area, clinical + regulatory + financial)

**Current News Context**:
- Eli Lilly $1T market cap driven by obesity portfolio
- Novo Nordisk competing (semaglutide)
- Oral formulations in development
- Market size >$20B and growing rapidly
- Compounding pharmacy disruption

**Data Requirements**:
- Clinical trials: Phase 2/3 obesity drug trials (via `ct_gov_mcp`)
- FDA drugs: Approved obesity drugs (via `fda_mcp`)
- Financial: Lilly vs. Novo Nordisk stock performance (via `financials_mcp`)
- Publications: Real-world effectiveness data (via `pubmed_mcp`) [optional]

**Skills Likely Needed**:
```
get_obesity_phase3_recruiting_trials (ct_gov_mcp)
get_glp1_obesity_fda_drugs (fda_mcp)
get_eli_lilly_stock_data (financials_mcp)
get_novo_nordisk_stock_data (financials_mcp)
```

**Expected Analysis Output**:
1. **Current Market Leaders**:
   - Approved drugs: Mounjaro (Lilly), Wegovy (Novo), Zepbound (Lilly)
   - Market share distribution
   - Pricing and reimbursement
   - Sales trajectory

2. **Pipeline Competition**:
   - Late-stage programs by company
   - Oral vs. injectable formulations
   - Dosing frequency innovations (weekly, monthly)
   - Mechanism diversity (GLP-1, GLP-1/GIP, beyond GLP-1)

3. **Competitive Positioning Analysis**:
   - Efficacy benchmarking (% weight loss)
   - Safety profiles
   - Convenience factors
   - Patent protection timelines

4. **Market Sustainability Assessment**:
   - Total addressable market size
   - Patient access and reimbursement trends
   - Generic/biosimilar threats
   - Adjacent indications (NASH, sleep apnea)

5. **Valuation Sustainability**:
   - Is Lilly's $1T valuation justified?
   - Competitive threats timeline
   - R&D productivity required to maintain premium
   - Downside scenarios

**Capabilities Tested**:
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓✓ Financial & Investment Analysis
- ✓✓ Strategic Intelligence Synthesis
- ✓ Competitive positioning analysis
- ✓ Risk Assessment & Early Warning
- ✓✓ Action Planning & Recommendations

**Business Value**: Investment thesis validation, competitive strategy, portfolio prioritization

**Success Criteria**:
- Comprehensive market landscape (approved + pipeline)
- Quantitative competitive differentiation
- Valuation sustainability analysis
- Risk-adjusted recommendations

---

### Query L2.2: CAR-T Manufacturing Innovation Landscape

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the competitive landscape for CAR-T cell therapy manufacturing innovations. Who is solving the cost and scalability challenges?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Technology platform, trials + patents)

**Current News Context**:
- CAR-T pricing remains barrier ($373K-$475K per treatment)
- Manufacturing efficiency critical to COGS
- In vivo CAR-T reprogramming emerging (avoid ex vivo)
- Allogeneic (off-the-shelf) approaches
- Solid tumor applications expanding

**Data Requirements**:
- Clinical trials: Novel CAR-T manufacturing approaches (via `ct_gov_mcp`)
- Patents: CAR-T manufacturing innovations (via `uspto_patents_mcp`)
- FDA drugs: Approved CAR-T products (via `fda_mcp`)
- Financial: Company valuations focusing on manufacturing tech (via `financials_mcp`) [optional]

**Skills Likely Needed**:
```
get_cart_bcell_malignancies_trials (ct_gov_mcp)
get_cart_manufacturing_patents (uspto_patents_mcp)
get_cart_approved_drugs (fda_mcp)
```

**Expected Analysis Output**:
1. **Current Manufacturing Challenges**:
   - Autologous vs. allogeneic approaches
   - Manufacturing timeline (2-4 weeks)
   - Cost structure breakdown
   - Scalability limitations
   - Quality control and failure rates

2. **Innovation Landscape**:
   - In vivo CAR-T reprogramming (lipid nanoparticles, AAV)
   - Allogeneic CAR-T (universal donors, gene editing)
   - Automated manufacturing platforms
   - Decentralized manufacturing

3. **Competitive Intelligence**:
   - Companies leading in manufacturing innovation
   - Patent landscape (freedom-to-operate)
   - Clinical validation status
   - Partnerships (pharma + tech/manufacturing)

4. **Market Impact Assessment**:
   - Cost reduction potential (from $400K to target?)
   - Timeline to market for innovations
   - Regulatory pathway considerations
   - Patient access implications

5. **Strategic Recommendations**:
   - Technology platform priorities
   - Build vs. license decisions
   - Partnership opportunities
   - Investment allocation

**Capabilities Tested**:
- ✓✓ Technology platform assessment
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Partnership & Deal Intelligence
- ✓ Patent landscape analysis
- ✓✓ Strategic Intelligence Synthesis
- ✓✓ Action Planning & Recommendations

**Business Value**: Technology strategy, partnership evaluation, cost optimization, market access planning

**Success Criteria**:
- Comprehensive manufacturing innovation landscape
- Technology readiness assessment
- Competitive positioning by approach
- Clear strategic recommendations (build, license, partner)

---

### Query L2.3: KRAS Inhibitor Market Evolution

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the evolution of the KRAS inhibitor market from G12C to pan-KRAS approaches. What's the competitive outlook?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Precision oncology, trials + FDA + targets)

**Current News Context**:
- KRAS G12C inhibitors approved (sotorasib, adagrasib)
- G12D inhibitors in development (larger patient population)
- Pan-KRAS approaches emerging
- Combination strategies critical (resistance mechanisms)

**Data Requirements**:
- Clinical trials: KRAS inhibitor trials by mutation (via `ct_gov_mcp`)
- FDA drugs: Approved KRAS inhibitors (via `fda_mcp`)
- Targets: KRAS mutation genetics (via `opentargets_mcp`) [optional]
- Publications: Resistance mechanisms (via `pubmed_mcp`) [optional]

**Skills Likely Needed**:
```
get_kras_inhibitor_trials (ct_gov_mcp)
get_kras_inhibitor_fda_drugs (fda_mcp)
get_kras_target_validation (opentargets_mcp)
```

**Expected Analysis Output**:
1. **KRAS Mutation Landscape**:
   - G12C prevalence and indications (NSCLC, colorectal)
   - G12D prevalence (pancreatic, colorectal)
   - Other mutations (G12V, Q61, etc.)
   - Total patient populations by mutation

2. **Approved Therapies**:
   - Sotorasib (LUMAKRAS): efficacy, safety, market uptake
   - Adagrasib (KRAZATI): differentiation, positioning
   - Real-world effectiveness
   - Resistance patterns

3. **Pipeline Analysis**:
   - G12D inhibitors (clinical stage, mechanism)
   - Pan-KRAS approaches (mutation-agnostic)
   - Combination strategies (with MEK inhibitors, checkpoint inhibitors)
   - Novel mechanisms (molecular glues, PROTACs)

4. **Competitive Landscape**:
   - First-generation vs. next-generation inhibitors
   - Efficacy benchmarking
   - Safety differentiation
   - Combination therapy opportunities

5. **Market Evolution**:
   - G12C market saturation timeline
   - G12D opportunity size
   - Expansion into earlier lines of therapy
   - Adjuvant/neoadjuvant potential

**Capabilities Tested**:
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓✓ Therapeutic Area Specialization (oncology)
- ✓ Target validation analysis
- ✓✓ Strategic Intelligence Synthesis
- ✓ Market evolution forecasting

**Business Value**: Target selection strategy, clinical development planning, market entry timing, competitive differentiation

**Success Criteria**:
- Clear mutation-specific landscape
- Pipeline depth analysis by mutation
- Competitive positioning assessment
- Market evolution timeline and opportunities

---

### Query L2.4: Alzheimer's Disease Beyond Anti-Amyloid

**User Input**:
```
@agent-competitive-landscape-analyst "With lecanemab and donanemab approved showing modest benefits, what's the competitive landscape for next-generation Alzheimer's therapies?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Therapeutic area, trials + FDA + literature)

**Current News Context**:
- Lecanemab approved July 2023, donanemab July 2024
- Both show ~27% slowing of cognitive decline (modest)
- ARIA (amyloid-related imaging abnormalities) safety concerns
- APOE4 genotype risk stratification required
- Need for alternative mechanisms recognized

**Data Requirements**:
- Clinical trials: Alzheimer's Phase 2/3 trials by mechanism (via `ct_gov_mcp`)
- FDA drugs: Approved Alzheimer's drugs (via `fda_mcp`)
- Targets: Alzheimer's therapeutic targets beyond amyloid (via `opentargets_mcp`)
- Publications: Mechanism diversity research (via `pubmed_mcp`) [optional]

**Skills Likely Needed**:
```
get_alzheimers_phase3_trials (ct_gov_mcp)
get_alzheimers_fda_drugs (fda_mcp)
get_alzheimers_therapeutic_targets (opentargets_mcp)
```

**Expected Analysis Output**:
1. **Anti-Amyloid Therapy Assessment**:
   - Lecanemab and donanemab efficacy data
   - ARIA safety profile and monitoring requirements
   - APOE4 genotype considerations
   - Real-world uptake challenges
   - Clinical meaningfulness debate

2. **Mechanism Diversity Analysis**:
   - Tau-targeting therapies (antibodies, small molecules)
   - Neuroinflammation approaches (microglia modulation)
   - Synaptic targets (nicotinic receptors, NMDA)
   - Multi-mechanism combinations
   - Disease-modifying vs. symptomatic

3. **Pipeline Assessment**:
   - Late-stage programs by mechanism
   - Novel targets in Phase 1/2
   - Biomarker-driven patient selection
   - Trial design evolution

4. **Competitive Positioning**:
   - Beyond amyloid opportunity size
   - Unmet needs post-anti-amyloid approval
   - Combination therapy potential
   - Earlier intervention strategies

5. **Strategic Outlook**:
   - Mechanism prioritization
   - Trial design recommendations
   - Patient selection strategies
   - Market access considerations

**Capabilities Tested**:
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓✓ Therapeutic Area Specialization (neurology)
- ✓ Target validation
- ✓✓ Risk Assessment (mechanism, clinical)
- ✓✓ Strategic Intelligence Synthesis

**Business Value**: Mechanism selection, clinical strategy, differentiation from standard of care, patient selection

**Success Criteria**:
- Mechanism diversity quantification
- Clinical validation status by approach
- Clear strategic recommendations
- Risk-benefit assessment vs. anti-amyloid therapies

---

### Query L2.5: Rare Disease FDA Regulatory Flexibility

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze how FDA's increasing regulatory flexibility for rare diseases is changing the orphan drug development landscape"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Regulatory strategy, trials + FDA)

**Current News Context**:
- 1,268 approved orphan drugs (FDA)
- FDA "plausible mechanism" pathway for personalized therapies (Nov 2025)
- Accelerated approval pathways more accessible
- Small patient population trial design evolution
- CRISPR personalized therapies setting precedent

**Data Requirements**:
- Clinical trials: Orphan drug trials with adaptive designs (via `ct_gov_mcp`)
- FDA drugs: Recent orphan drug approvals and pathways (via `fda_mcp`)
- Regulatory guidance: FDA breakthrough/orphan designations (via `fda_mcp`)

**Skills Likely Needed**:
```
get_orphan_neurological_drugs (fda_mcp)
get_orphan_neurological_trials (ct_gov_mcp)
get_breakthrough_therapy_designations_2024 (fda_mcp)
```

**Expected Analysis Output**:
1. **Regulatory Evolution**:
   - Historical approval standards vs. current flexibility
   - "Plausible mechanism" pathway details
   - Accelerated approval trends
   - Breakthrough therapy designation success rates

2. **Trial Design Innovations**:
   - Adaptive designs for small populations
   - Natural history as control arms
   - Basket and umbrella trials
   - Single-arm studies acceptance
   - Biomarker-based endpoints

3. **Recent Approval Case Studies**:
   - Casgevy (CRISPR for sickle cell) - personalized approach
   - Other 2024/2025 orphan approvals
   - Surrogate endpoints accepted
   - Post-marketing requirements

4. **Competitive Landscape**:
   - Which companies leveraging flexibility effectively
   - Therapeutic areas most active
   - Technology platforms (gene therapy, ASOs, etc.)
   - Partnership patterns (academia to biotech to pharma)

5. **Strategic Implications**:
   - Portfolio expansion opportunities
   - Development timeline acceleration
   - Risk mitigation strategies
   - Regulatory meeting strategies

**Capabilities Tested**:
- ✓✓ Regulatory strategy analysis
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓ Risk Assessment
- ✓✓ Strategic Intelligence Synthesis
- ✓✓ Action Planning & Recommendations

**Business Value**: Regulatory strategy optimization, portfolio expansion into rare disease, timeline acceleration, risk management

**Success Criteria**:
- Clear documentation of regulatory flexibility evolution
- Trial design innovation assessment
- Actionable regulatory pathway recommendations
- Portfolio strategy implications

---

### Query L2.6: Checkpoint Inhibitor Combination Therapy Landscape

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the competitive landscape for checkpoint inhibitor combination therapies. Which combinations are winning and why?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Intermediate (Combinations, trials + FDA + safety)

**Current News Context**:
- KEYTRUDA + PADCEV combo just approved (bladder cancer)
- Checkpoint + chemotherapy standard in many indications
- Checkpoint + checkpoint combos (CTLA-4 + PD-1)
- Checkpoint + targeted therapy emerging
- Biomarker-driven selection critical

**Data Requirements**:
- Clinical trials: Checkpoint inhibitor combination trials (via `ct_gov_mcp`)
- FDA drugs: Approved checkpoint inhibitor combos (via `fda_mcp`)
- Adverse events: Combination safety profiles (via `fda_mcp`)
- Publications: Combination synergy mechanisms (via `pubmed_mcp`) [optional]

**Skills Likely Needed**:
```
get_checkpoint_inhibitor_combination_trials (ct_gov_mcp)
get_checkpoint_inhibitor_fda_drugs (fda_mcp)
get_checkpoint_inhibitor_adverse_events (fda_mcp)
```

**Expected Analysis Output**:
1. **Approved Combinations**:
   - Checkpoint + chemotherapy (NSCLC, breast, etc.)
   - Checkpoint + checkpoint (ipilimumab + nivolumab)
   - Checkpoint + targeted therapy (BRAF/MEK, KRAS)
   - Checkpoint + ADC (KEYTRUDA + PADCEV)
   - Efficacy benchmarking

2. **Pipeline Combinations**:
   - Late-stage programs by combination type
   - Novel partner classes (cell therapy, oncolytic virus, etc.)
   - Mechanism-based rationale
   - Biomarker strategies

3. **Safety Profile Analysis**:
   - Immune-related adverse events (irAEs)
   - Combination toxicity vs. monotherapy
   - Management protocols
   - Patient selection to mitigate risk

4. **Competitive Intelligence**:
   - Leading combination developers
   - Partnership patterns (checkpoint + targeted drug from different companies)
   - Market share by combination type
   - Reimbursement landscape

5. **Strategic Recommendations**:
   - Most promising combination classes
   - Partner drug selection criteria
   - Biomarker development priorities
   - Trial design optimization

**Capabilities Tested**:
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓ Safety surveillance analysis
- ✓✓ Strategic Intelligence Synthesis
- ✓ Partnership & Deal Intelligence
- ✓✓ Therapeutic Area Specialization (oncology)

**Business Value**: Combination strategy, partnership identification, trial design, market differentiation

**Success Criteria**:
- Comprehensive combination landscape
- Safety differentiation analysis
- Mechanism-based prioritization
- Partnership strategy recommendations

---

## LEVEL 3: Advanced Multi-Domain Queries

**Purpose**: Test deep competitive intelligence requiring 4-6 data sources and sophisticated analysis. Includes patent landscape, financial modeling, and partnership intelligence.

**Expected Runtime**: 20-40 minutes per query
**Expected Output**: 3000-5000 word report
**Data Requirements**: 4-6 skills (trials + FDA + patents + financial + publications)

---

### Query L3.1: GLP-1 Oral Formulation Technology Race

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the competitive landscape for oral GLP-1 formulation technologies. Evaluate IP positions, clinical progress, and commercial potential."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Multi-domain: chemistry, patents, trials, FDA, financial)

**Current News Context**:
- Novo Nordisk's oral semaglutide uses SNAC technology (licensed)
- Eli Lilly's orforglipron designed oral-first
- Oral bioavailability major challenge for peptides (<1%)
- Market preference shifting toward oral formulations
- Multiple competing absorption enhancement technologies

**Data Requirements**:
- Patents: Oral formulation technologies (SNAC, permeation enhancers) (via `uspto_patents_mcp`)
- Clinical trials: Oral GLP-1 trials (via `ct_gov_mcp`)
- FDA drugs: Approved oral GLP-1 products (via `fda_mcp`)
- Chemistry: GLP-1 agonist properties (via `pubchem_mcp`)
- Publications: Absorption technology research (via `pubmed_mcp`)
- Financial: Licensing deal comparables (via `sec_edgar_mcp`)

**Skills Likely Needed**:
```
get_glp1_obesity_patents (uspto_patents_mcp)
get_oral_glp1_trials (ct_gov_mcp)
get_glp1_fda_drugs (fda_mcp)
get_glp1_agonist_properties (pubchem_mcp)
get_oral_peptide_formulation_publications (pubmed_mcp)
get_pharma_licensing_deals (sec_edgar_mcp)
```

**Expected Analysis Output**:
1. **Technology Landscape**:
   - SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate)
   - Permeation enhancers (chitosan, medium-chain fatty acids)
   - Protease inhibitors (co-formulation)
   - Nanoparticle delivery systems
   - Prodrug approaches
   - Chemical modification strategies

2. **Patent Landscape & Freedom-to-Operate**:
   - Key patent holders (Emisphere, others)
   - Patent expiry timelines
   - Licensing requirements
   - Freedom-to-operate for each technology
   - Litigation history

3. **Clinical Validation**:
   - Oral semaglutide: efficacy vs. injectable, dosing (3mg, 7mg, 14mg, 25mg pending)
   - Orforglipron: Phase 3 data, dosing, vs. semaglutide head-to-head
   - Other programs: early vs. late stage
   - Bioavailability achieved by technology
   - Safety profiles (GI tolerability)

4. **Competitive Positioning**:
   - Technology leaders by approach
   - Clinical stage progression
   - Commercial launch timelines
   - Market access and payer preferences

5. **Financial Analysis**:
   - Technology licensing deal values
   - Royalty rate benchmarks
   - Development costs oral vs. injectable
   - Market premium for oral formulations
   - Revenue projections

6. **Strategic Recommendations**:
   - Build vs. license decision framework
   - Technology platform prioritization
   - Partnership target identification
   - Development timeline optimization
   - Risk mitigation strategies

**Capabilities Tested**:
- ✓✓✓ Technology platform assessment
- ✓✓✓ Patent landscape analysis
- ✓✓✓ Pipeline Intelligence & Tracking
- ✓✓ Chemical properties analysis
- ✓✓✓ Partnership & Deal Intelligence
- ✓✓✓ Financial & Investment Analysis
- ✓✓✓ Strategic Intelligence Synthesis

**Business Value**: Technology strategy, licensing decisions, IP risk assessment, portfolio optimization, competitive differentiation

**Success Criteria**:
- Comprehensive technology landscape
- Clear IP/FTO assessment
- Clinical validation status
- Financial modeling (licensing vs. internal development)
- Actionable build/license/partner recommendations

---

### Query L3.2: Cell Therapy Acquisition Target Identification

**User Input**:
```
@agent-competitive-landscape-analyst "Identify the top 3-5 acquisition targets in cell therapy with differentiated technology platforms. Provide valuation ranges and strategic rationale."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Multi-domain: trials, patents, financial, publications, M&A benchmarking)

**Current News Context**:
- Big Pharma M&A activity ($150B in 2025)
- Cell therapy technology platforms diversifying
- In vivo CAR-T reprogramming emerging
- Allogeneic approaches reducing COGS
- Solid tumor applications expanding

**Data Requirements**:
- Clinical trials: Novel cell therapy approaches (via `ct_gov_mcp`)
- Patents: Cell therapy technology platforms (via `uspto_patents_mcp`)
- Financial: Private biotech valuations, funding rounds (via `financials_mcp`, `sec_edgar_mcp`)
- Publications: Technology differentiation (via `pubmed_mcp`)
- M&A: Recent cell therapy acquisition comps (via `sec_edgar_mcp`)

**Skills Likely Needed**:
```
get_cart_novel_approaches_trials (ct_gov_mcp)
get_cell_therapy_manufacturing_patents (uspto_patents_mcp)
get_biotech_ma_deals_cell_therapy (sec_edgar_mcp)
get_cell_therapy_technology_publications (pubmed_mcp)
get_private_biotech_valuations (financials_mcp)
```

**Expected Analysis Output**:
1. **Target Identification Criteria**:
   - Technology differentiation (in vivo, allogeneic, solid tumor)
   - Clinical validation status (Phase 1, Phase 2 data)
   - IP strength and freedom-to-operate
   - Management team quality
   - Scalability and COGS potential
   - Strategic fit considerations

2. **Technology Platform Assessment**:
   - In vivo CAR-T reprogramming (LNP, AAV delivery)
   - Allogeneic CAR-T (gene editing, universal donors)
   - Solid tumor trafficking enhancements
   - Manufacturing automation platforms
   - Novel targets beyond CD19/BCMA

3. **Top 3-5 Acquisition Targets**:
   For each target:
   - Company overview and technology platform
   - Clinical pipeline status
   - Patent portfolio strength
   - Competitive differentiation
   - Management and scientific advisors
   - Funding history and burn rate
   - Valuation range (based on comps)
   - Strategic rationale for acquisition

4. **M&A Comparables Analysis**:
   - Recent cell therapy acquisitions (deal value, stage, technology)
   - Valuation multiples by stage
   - Premium paid for differentiation
   - Deal structure trends (upfront, milestones, CVRs)

5. **Integration Assessment**:
   - Technology integration complexity
   - Regulatory pathway preservation
   - Talent retention strategies
   - Manufacturing infrastructure needs
   - Synergy opportunities

6. **Risk Assessment**:
   - Clinical failure risk
   - Regulatory risk
   - Manufacturing scale-up risk
   - Competitive risk (others acquiring similar assets)
   - IP litigation risk

**Capabilities Tested**:
- ✓✓✓ Partnership & Deal Intelligence
- ✓✓✓ Technology platform assessment
- ✓✓✓ Financial & Investment Analysis
- ✓✓✓ Pipeline Intelligence & Tracking
- ✓✓✓ Risk Assessment & Early Warning
- ✓✓ Patent landscape analysis
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓✓ Action Planning & Recommendations

**Business Value**: M&A strategy, target prioritization, valuation modeling, due diligence preparation, negotiation strategy

**Success Criteria**:
- 3-5 prioritized acquisition targets
- Clear differentiation rationale
- Valuation ranges with methodology
- Risk-adjusted recommendations
- Deal structure suggestions
- Integration roadmap

---

### Query L3.3: Alzheimer's Anti-Amyloid Market Access Challenges

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the market access challenges for anti-amyloid Alzheimer's therapies. Evaluate pricing, reimbursement, ARIA monitoring costs, and commercial viability."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Multi-domain: clinical, regulatory, financial, provider, real-world evidence)

**Current News Context**:
- Lecanemab and donanemab approved with high price tags
- CMS coverage decisions critical
- ARIA monitoring requires frequent MRI (expensive)
- APOE4 genotyping required
- Modest efficacy (~27% slowing) vs. high cost/monitoring burden
- Real-world uptake slower than expected

**Data Requirements**:
- FDA drugs: Lecanemab/donanemab approval details and labels (via `fda_mcp`)
- Clinical trials: Real-world effectiveness studies (via `ct_gov_mcp`, `pubmed_mcp`)
- CMS: Reimbursement policies and provider patterns (via `healthcare_mcp`)
- Financial: Pricing, revenue projections (via `financials_mcp`, `sec_edgar_mcp`)
- Publications: ARIA monitoring protocols, cost-effectiveness (via `pubmed_mcp`)
- Adverse events: ARIA incidence and severity (via `fda_mcp`)

**Skills Likely Needed**:
```
get_alzheimers_anti_amyloid_fda_drugs (fda_mcp)
get_alzheimers_real_world_studies (pubmed_mcp)
get_alzheimers_prescriber_patterns (healthcare_mcp)
get_biogen_eisai_financials (financials_mcp)
get_anti_amyloid_adverse_events (fda_mcp)
```

**Expected Analysis Output**:
1. **Product Profile**:
   - Lecanemab (Leqembi): dosing, efficacy, safety
   - Donanemab (Kisunla): dosing, efficacy, safety
   - Comparative effectiveness
   - Label differences

2. **Pricing & Reimbursement Landscape**:
   - Annual treatment cost ($26K-$32K range)
   - CMS coverage decisions (national vs. regional)
   - Private payer policies
   - Prior authorization requirements
   - Step therapy protocols

3. **ARIA Monitoring Requirements & Costs**:
   - MRI frequency (baseline, months 5-7, 9, 12, etc.)
   - MRI cost per scan ($500-$3000)
   - Total monitoring cost over treatment duration
   - APOE4 genotyping requirement and cost
   - Neurologist follow-up visits
   - Total cost of care (drug + monitoring)

4. **Clinical Benefit vs. Cost Analysis**:
   - Efficacy: ~27% slowing of decline (CDR-SB scale)
   - Clinical meaningfulness debate
   - Quality-adjusted life years (QALY)
   - Cost-effectiveness ratios vs. willingness-to-pay thresholds
   - Comparison to symptomatic therapies

5. **Real-World Uptake Analysis**:
   - Prescriber adoption rates
   - Patient eligibility and filtering (APOE4 considerations)
   - Infusion center capacity constraints
   - Geographic access disparities
   - Payer rejection rates

6. **Competitive Landscape Impact**:
   - Impact on next-generation anti-amyloid programs
   - Implications for alternative mechanism therapies
   - Patient access programs and assistance
   - Political and advocacy pressure on payers

7. **Strategic Recommendations**:
   - Market access optimization strategies
   - Pricing strategy for followers
   - Monitoring cost reduction approaches
   - Patient selection refinement (enrichment strategies)
   - Real-world evidence generation priorities

**Capabilities Tested**:
- ✓✓✓ Financial & Investment Analysis
- ✓✓✓ Market access and reimbursement strategy
- ✓✓ Clinical Trial Monitoring (real-world evidence)
- ✓✓ Risk Assessment & Early Warning
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓ Healthcare provider analysis
- ✓✓✓ Action Planning & Recommendations

**Business Value**: Pricing strategy, market access planning, commercial forecasting, portfolio prioritization, real-world evidence strategy

**Success Criteria**:
- Comprehensive cost-of-care analysis
- Clear market access barrier identification
- Quantitative uptake forecasting
- Competitive implications assessment
- Actionable market access strategies

---

### Query L3.4: CRISPR Gene Editing IP Landscape Navigation

**User Input**:
```
@agent-competitive-landscape-analyst "Map the CRISPR gene editing patent landscape. Who owns what rights? What are the freedom-to-operate implications for therapeutic applications?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Complex IP landscape, patents + trials + licensing deals)

**Current News Context**:
- Casgevy (CRISPR/Cas9 for sickle cell) approved Dec 2023
- FDA "plausible mechanism" pathway for personalized CRISPR (Nov 2025)
- Broad Institute vs. UC Berkeley patent disputes
- Multiple commercial CRISPR companies (Editas, CRISPR Therapeutics, Intellia)
- Next-generation editors (base editing, prime editing)

**Data Requirements**:
- Patents: CRISPR patent families across institutions/companies (via `uspto_patents_mcp`)
- Clinical trials: CRISPR therapeutic programs (via `ct_gov_mcp`)
- M&A/Licensing: CRISPR licensing deals and valuations (via `sec_edgar_mcp`)
- Publications: CRISPR IP landscape analyses (via `pubmed_mcp`)

**Skills Likely Needed**:
```
get_crispr_ip_landscape (uspto_patents_mcp)
get_crispr_therapeutic_trials (ct_gov_mcp)
get_crispr_licensing_deals (sec_edgar_mcp)
get_crispr_ip_publications (pubmed_mcp)
```

**Expected Analysis Output**:
1. **Core CRISPR IP Ownership**:
   - Broad Institute (Cas9 in eukaryotes): patent scope, expiry, claims
   - UC Berkeley (Doudna/Charpentier): patent scope, expiry, claims
   - Patent dispute history and current status
   - Geographic coverage (US, EU, Asia)

2. **Commercial CRISPR Company IP Positions**:
   - Editas Medicine: exclusive Broad licenses
   - CRISPR Therapeutics: UC Berkeley licenses
   - Intellia Therapeutics: patent positions
   - Beam Therapeutics: base editing IP
   - Prime Medicine: prime editing IP
   - Cross-licensing agreements

3. **Therapeutic Application IP**:
   - Ex vivo vs. in vivo delivery (LNP, AAV)
   - Disease-specific applications (sickle cell, beta-thalassemia, etc.)
   - Tissue-specific delivery
   - Guide RNA design
   - Off-target minimization technologies

4. **Freedom-to-Operate Analysis**:
   - Licensing requirements for therapeutic development
   - Royalty stacking considerations
   - Patent thickets and navigation strategies
   - Litigation risk assessment
   - Geographic FTO variations

5. **Next-Generation Editing IP**:
   - Base editing (adenine, cytosine base editors)
   - Prime editing
   - Epigenetic editing
   - RNA editing (ADAR-based)
   - Patent filing activity and trends

6. **Licensing Deal Benchmarking**:
   - Academic → biotech licensing terms
   - Biotech → pharma sublicensing
   - Royalty rates and milestone structures
   - Upfront payments and deal values

7. **Strategic Recommendations**:
   - Build vs. license strategies by application
   - Licensing partner selection
   - IP risk mitigation approaches
   - Internal IP development priorities
   - Litigation avoidance strategies

**Capabilities Tested**:
- ✓✓✓ Patent landscape analysis (deep)
- ✓✓✓ Partnership & Deal Intelligence
- ✓✓ Pipeline Intelligence & Tracking
- ✓✓✓ Risk Assessment & Early Warning (IP)
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓ Technology platform assessment
- ✓✓✓ Action Planning & Recommendations

**Business Value**: IP strategy, licensing decisions, FTO assessment, litigation risk management, partnership negotiations

**Success Criteria**:
- Comprehensive patent ownership mapping
- Clear FTO assessment by therapeutic area
- Licensing deal benchmarking
- Risk-adjusted IP strategy recommendations
- Litigation risk evaluation

---

### Query L3.5: Oncology Biosimilar Impact on Biologics Market

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the impact of biosimilars on the oncology biologics market. Which franchises are most at risk? What are the strategic responses?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Multi-domain: FDA approvals, market share shifts, financial impact, competitive responses)

**Data Requirements**:
- FDA drugs: Biosimilar approvals in oncology (via `fda_mcp`)
- Clinical trials: Biosimilar clinical trials and originator response trials (via `ct_gov_mcp`)
- Financial: Originator revenue erosion, biosimilar market share (via `financials_mcp`)
- CMS: Biosimilar uptake and reimbursement (via `healthcare_mcp`)
- Patents: Originator patent expiries (via `uspto_patents_mcp`)

**Skills Likely Needed**:
```
get_biosimilar_oncology_approvals (fda_mcp)
get_biosimilar_oncology_trials (ct_gov_mcp)
get_originator_biosimilar_financials (financials_mcp)
get_biosimilar_patent_landscape (uspto_patents_mcp)
get_biosimilar_prescribing_patterns (healthcare_mcp)
```

**Expected Analysis Output**:
1. **Oncology Biosimilar Landscape**:
   - Approved biosimilars: Herceptin (trastuzumab), Avastin (bevacizumab), Rituxan (rituximab), etc.
   - Launch dates and uptake curves
   - Pricing dynamics (discount to originator)
   - Market share erosion timelines

2. **Franchises at Risk**:
   - Herceptin franchise: revenue loss timeline, biosimilar penetration
   - Avastin franchise: multi-indication impact
   - Keytruda (pembrolizumab): future biosimilar threat (2028+ patent expiry)
   - Opdivo (nivolumab): biosimilar timeline
   - Patent cliff analysis by product

3. **Financial Impact Assessment**:
   - Revenue erosion quantification (historical and projected)
   - Margin compression
   - Impact on originator company valuations
   - Biosimilar manufacturer revenue opportunity
   - Market share redistribution

4. **Originator Strategic Responses**:
   - Life cycle management (new formulations, combinations, indications)
   - Next-generation molecule development
   - Authorized biosimilars strategies
   - Patent litigation and settlements
   - Pricing strategies (maintain vs. compete)

5. **Market Access Dynamics**:
   - Payer preferences and formulary positioning
   - Interchangeability designations (impact on uptake)
   - Provider and patient acceptance
   - Biosimilar switching studies
   - Value-based contracting evolution

6. **Competitive Landscape Evolution**:
   - Biosimilar manufacturer positioning
   - Originator-biosimilar partnerships
   - Generic vs. branded biosimilar strategies
   - International market dynamics (EU ahead of US)

7. **Strategic Recommendations**:
   - Portfolio diversification priorities
   - Life cycle management acceleration
   - Biosimilar defense vs. embrace strategies
   - Pricing and market access optimization
   - M&A to offset biosimilar impact

**Capabilities Tested**:
- ✓✓✓ Financial & Investment Analysis
- ✓✓ Risk Assessment & Early Warning
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓ Market access analysis
- ✓✓ Patent landscape analysis
- ✓✓✓ Competitive positioning
- ✓✓✓ Action Planning & Recommendations

**Business Value**: Portfolio risk assessment, life cycle management planning, financial forecasting, competitive strategy, M&A prioritization

**Success Criteria**:
- Quantitative biosimilar impact analysis
- Franchise-specific risk assessment
- Strategic response evaluation
- Actionable recommendations for originators and biosimilar developers

---

### Query L3.6: Precision Oncology Biomarker Landscape

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the precision oncology biomarker landscape. Which biomarkers are driving drug development? What are the companion diagnostics implications?"
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Advanced (Multi-domain: targets, trials, FDA, diagnostics, publications)

**Data Requirements**:
- Targets: Biomarker-disease associations (via `opentargets_mcp`)
- Clinical trials: Biomarker-selected trials (via `ct_gov_mcp`)
- FDA drugs: Biomarker-based approvals (via `fda_mcp`)
- Publications: Biomarker discovery and validation (via `pubmed_mcp`)
- CMS: Diagnostic test reimbursement (via `healthcare_mcp`) [optional]

**Skills Likely Needed**:
```
get_cancer_biomarker_targets (opentargets_mcp)
get_biomarker_selected_oncology_trials (ct_gov_mcp)
get_biomarker_based_oncology_approvals (fda_mcp)
get_biomarker_validation_publications (pubmed_mcp)
```

**Expected Analysis Output**:
1. **Biomarker Categories**:
   - Genomic: mutations (KRAS G12C, EGFR, BRAF V600E)
   - Genomic: amplifications/deletions (HER2, MET exon 14)
   - Genomic: fusions (ALK, ROS1, NTRK)
   - Protein expression: PD-L1, HER2 IHC
   - Tumor mutational burden (TMB)
   - Microsatellite instability (MSI-H/dMMR)
   - Circulating tumor DNA (ctDNA)

2. **Biomarker-Drug Development Landscape**:
   - KRAS G12C: sotorasib, adagrasib (approved)
   - KRAS G12D: programs in development
   - EGFR mutations: osimertinib and competitors
   - HER2: T-DXd and other ADCs
   - NTRK fusions: larotrectinib, entrectinib
   - MSI-H: checkpoint inhibitors
   - PD-L1: checkpoint inhibitor companion diagnostics

3. **Clinical Trial Design Evolution**:
   - Basket trials (biomarker across tumor types)
   - Umbrella trials (multiple biomarkers, one tumor type)
   - Biomarker enrichment strategies
   - Adaptive trial designs based on biomarker subgroups
   - Real-world evidence for biomarker validation

4. **Companion Diagnostics Landscape**:
   - FDA-approved companion diagnostics
   - Diagnostic platform technologies (NGS, IHC, FISH)
   - Tissue vs. liquid biopsy approaches
   - Multiplexed vs. single biomarker tests
   - Turnaround time and access considerations

5. **Regulatory Pathway**:
   - Co-development of drug + diagnostic
   - Retrospective biomarker validation
   - Label restrictions by biomarker
   - Post-market biomarker expansion

6. **Market Access & Reimbursement**:
   - Diagnostic test reimbursement landscape
   - Patient access to testing
   - Testing algorithm optimization
   - Cost-effectiveness of biomarker-guided therapy

7. **Strategic Recommendations**:
   - Biomarker prioritization for drug development
   - Companion diagnostic partnership strategies
   - Trial design optimization for biomarker validation
   - Market access strategy for biomarker-selected therapies
   - Biomarker expansion roadmap

**Capabilities Tested**:
- ✓✓✓ Target validation analysis
- ✓✓✓ Pipeline Intelligence & Tracking
- ✓✓ Clinical Trial Monitoring
- ✓✓ Therapeutic Area Specialization (oncology)
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓ Partnership & Deal Intelligence (diagnostics)
- ✓✓✓ Action Planning & Recommendations

**Business Value**: Target selection, trial design optimization, companion diagnostic strategy, patient segmentation, market access planning

**Success Criteria**:
- Comprehensive biomarker landscape
- Biomarker-drug pairing analysis
- Companion diagnostic strategic assessment
- Actionable biomarker development roadmap

---

## LEVEL 4: Strategic Synthesis Queries

**Purpose**: Test full competitive landscape analysis requiring comprehensive multi-domain data synthesis. Board-ready strategic reports with investment recommendations.

**Expected Runtime**: 40-60 minutes per query
**Expected Output**: 4000-6000 word strategic report
**Data Requirements**: 6+ skills (trials + FDA + patents + financial + publications + CMS)

---

### Query L4.1: Comprehensive Obesity Drug Market Strategic Analysis

**User Input**:
```
@agent-competitive-landscape-analyst "Provide a comprehensive competitive landscape analysis for the obesity drug market. Cover approved therapies, pipeline, market dynamics, patent landscape, pricing/access, and provide strategic recommendations for a company considering market entry."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Strategic Synthesis (Full competitive landscape, all data domains)

**Current News Context**:
- Eli Lilly $1T market cap (obesity-driven)
- Market size >$20B and growing rapidly
- Oral formulations in development (game-changer potential)
- Compounding pharmacy disruption
- Reimbursement expansion underway
- Adjacent indications expanding (NASH, sleep apnea, cardiovascular)

**Data Requirements**:
- Clinical trials: Obesity drug trials by phase and mechanism (via `ct_gov_mcp`)
- FDA drugs: Approved obesity drugs (via `fda_mcp`)
- Patents: GLP-1 and obesity drug patents (via `uspto_patents_mcp`)
- Financial: Lilly, Novo, others stock performance and revenue (via `financials_mcp`)
- Publications: Real-world effectiveness, mechanism research (via `pubmed_mcp`)
- CMS: Prescribing patterns, reimbursement (via `healthcare_mcp`)
- Chemistry: GLP-1 agonist properties (via `pubchem_mcp`)
- M&A: Obesity drug deals and valuations (via `sec_edgar_mcp`)

**Skills Likely Needed** (8-10 skills):
```
get_obesity_phase3_recruiting_trials (ct_gov_mcp)
get_obesity_phase2_trials (ct_gov_mcp)
get_glp1_obesity_fda_drugs (fda_mcp)
get_glp1_obesity_patents (uspto_patents_mcp)
get_eli_lilly_financials (financials_mcp)
get_novo_nordisk_financials (financials_mcp)
get_glp1_real_world_effectiveness (pubmed_mcp)
get_glp1_prescribing_patterns (healthcare_mcp)
get_glp1_agonist_properties (pubchem_mcp)
get_obesity_drug_ma_deals (sec_edgar_mcp)
```

**Expected Analysis Output** (4000-6000 words):

### 1. Executive Summary (500 words)
- Market size and growth trajectory
- Competitive intensity assessment
- Key strategic insights
- Investment recommendation summary

### 2. Approved Therapy Landscape (800 words)
- **GLP-1 Agonists**:
  - Wegovy (semaglutide 2.4mg) - Novo Nordisk
  - Saxenda (liraglutide) - Novo Nordisk
  - Zepbound (tirzepatide) - Eli Lilly
  - Mounjaro (tirzepatide, diabetes indication) - Eli Lilly
- **Efficacy Benchmarking**: % weight loss at 68 weeks
- **Safety Profiles**: GI tolerability, cardiovascular outcomes
- **Market Share**: Revenue, prescriptions, trends
- **Pricing**: WAC, net pricing, discounts
- **Formulations**: Injectable (weekly), oral (pending)

### 3. Clinical Pipeline Analysis (1000 words)
- **Late-Stage Programs (Phase 3)**:
  - Oral semaglutide 25mg (Novo): pivotal data, FDA filing timeline
  - Orforglipron (Lilly): oral-first design, head-to-head vs. semaglutide
  - Cagrilintide combinations (Novo): multi-agonist approach
  - Other GLP-1/GIP/glucagon triple agonists
  - Beyond GLP-1 mechanisms
- **Mid-Stage Programs (Phase 2)**: Novel mechanisms, combination approaches
- **Mechanism Diversity**: GLP-1, GLP-1/GIP, GLP-1/GIP/glucagon, non-GLP-1
- **Differentiation Strategies**: Efficacy, safety, convenience, cost
- **Development Timeline**: Market entry predictions by program

### 4. Patent Landscape & IP Strategy (600 words)
- **Composition of Matter**: Core GLP-1 molecule patents, expiry dates
- **Formulation Patents**: Oral delivery technologies (SNAC, etc.)
- **Method of Use**: Obesity indication patents
- **Patent Cliff Analysis**: Generic entry timelines
- **Freedom-to-Operate**: New entrant IP considerations
- **Licensing Landscape**: Technology licensing requirements

### 5. Market Dynamics & Sizing (700 words)
- **Total Addressable Market**: Obesity prevalence, treatment-eligible population
- **Market Growth Drivers**: Awareness, efficacy data, reimbursement expansion
- **Market Segmentation**: BMI categories, comorbidities, demographics
- **Geographic Analysis**: US, EU, Asia opportunity sizing
- **Adjacent Indications**: NASH, sleep apnea, cardiovascular risk reduction
- **Market Share Projections**: 2025-2030 forecasts

### 6. Pricing & Market Access (600 words)
- **Pricing Landscape**: Current WAC pricing ($900-$1,350/month)
- **Reimbursement Status**: Medicare, Medicaid, commercial payers
- **Prior Authorization**: Requirements and barriers
- **Patient Access Programs**: Affordability and adherence support
- **Value-Based Contracting**: Outcomes-based pricing models
- **International Pricing**: Reference pricing implications

### 7. Competitive Intelligence (600 words)
- **Competitive Positioning Matrix**: Efficacy, safety, convenience, cost
- **Competitive Response Scenarios**: Lilly vs. Novo strategies
- **Barriers to Entry**: Clinical data requirements, manufacturing scale, distribution
- **Competitive Advantages**: First-mover vs. fast-follower vs. best-in-class
- **Partnership Landscape**: Co-promotion, licensing, distribution deals

### 8. Risk Assessment (400 words)
- **Clinical Risks**: Long-term safety unknowns, muscle mass loss, rebound weight gain
- **Regulatory Risks**: Label restrictions, safety warnings
- **Commercial Risks**: Reimbursement retraction, compounding pharmacy competition
- **Competitive Risks**: Better-than-GLP-1 mechanisms, oral formulations disrupting injectables
- **Manufacturing Risks**: Supply chain, capacity constraints

### 9. Strategic Recommendations (800 words)

**For New Market Entrants**:
- **Entry Strategy**: Best-in-class vs. fast-follower
- **Mechanism Selection**: GLP-1 follow-on vs. beyond GLP-1
- **Formulation Strategy**: Oral vs. injectable vs. both
- **Development Timeline**: Accelerated pathway opportunities
- **Partnership vs. Internal**: Build vs. acquire vs. license
- **Investment Requirements**: Clinical development, manufacturing, commercial

**For Existing Players**:
- **Portfolio Optimization**: Life cycle management, next-generation molecules
- **Market Access Strategy**: Payer negotiations, patient access programs
- **Geographic Expansion**: International market prioritization
- **Adjacent Indications**: Indication expansion strategies
- **Biosimilar Defense**: Patent extension, authorized biosimilar strategies

**For Investors**:
- **Company Recommendations**: Buy/Hold/Sell ratings for Lilly, Novo, others
- **Risk-Adjusted Returns**: Probability-weighted valuations
- **Portfolio Allocation**: Obesity exposure recommendations
- **Catalyst Monitoring**: Key data readouts, regulatory decisions

### 10. Appendices
- Data sources and methodology
- Key assumptions and limitations
- Company contact information for partnerships

**Capabilities Tested (Comprehensive)**:
- ✓✓✓ Pipeline Intelligence & Tracking
- ✓✓✓ Clinical Trial Monitoring & Analysis
- ✓✓✓ Financial & Investment Analysis
- ✓✓✓ Strategic Intelligence Synthesis
- ✓✓✓ Data Collection & Source Management
- ✓✓✓ Analytical Frameworks & Modeling
- ✓✓✓ Reporting & Communication
- ✓✓ Technology & Automation
- ✓✓✓ Therapeutic Area Specialization
- ✓✓✓ Partnership & Deal Intelligence
- ✓✓✓ Risk Assessment & Early Warning
- ✓✓✓ Action Planning & Recommendations

**Business Value**: Portfolio investment decisions, market entry strategy, M&A targeting, competitive positioning, financial forecasting

**Success Criteria**:
- Comprehensive 4000-6000 word strategic report
- Multi-domain data synthesis (8-10 data sources)
- Quantitative analysis throughout
- Clear strategic recommendations with rationale
- Board-ready presentation quality
- Report saved to `reports/competitive-landscape/2025-11-23_obesity-drug-market.md`

---

### Query L4.2: CAR-T Cell Therapy Market Strategic Landscape

**User Input**:
```
@agent-competitive-landscape-analyst "Provide a comprehensive strategic analysis of the CAR-T cell therapy market. Cover approved products, pipeline innovation, manufacturing challenges, pricing/access barriers, and recommend strategies for improving commercial viability."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Strategic Synthesis (Full landscape, technology platform focus)

**Data Requirements**: Trials, FDA, patents, financial, CMS, publications (6-8 skills)

**Expected Output**: 4000-6000 word report covering approved CAR-T products, manufacturing innovation landscape (in vivo, allogeneic), pricing/access challenges, solid tumor expansion, and strategic recommendations for improving commercial viability

**Capabilities Tested**: All 12 capabilities (comprehensive)

---

### Query L4.3: Alzheimer's Disease Therapeutic Landscape Beyond Anti-Amyloid

**User Input**:
```
@agent-competitive-landscape-analyst "Provide a comprehensive strategic analysis of the Alzheimer's disease therapeutic landscape. Evaluate anti-amyloid performance, alternative mechanisms in development, market access challenges, and recommend next-generation development strategies."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Strategic Synthesis (Full landscape, mechanism diversity)

**Data Requirements**: Trials, FDA, targets, publications, financial, CMS (6-8 skills)

**Expected Output**: 4000-6000 word report covering anti-amyloid therapy limitations, mechanism diversity pipeline (tau, inflammation, synaptic), market access challenges (ARIA monitoring, reimbursement), and strategic recommendations for next-generation Alzheimer's therapy development

**Capabilities Tested**: All 12 capabilities (comprehensive)

---

### Query L4.4: Global Oncology Clinical Development Geographic Strategy

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze global oncology clinical development strategy. Compare US vs. China vs. EU trial landscapes, evaluate regulatory alignment opportunities, and recommend geographic expansion strategies for maximizing speed-to-market and cost efficiency."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Strategic Synthesis (Geographic strategy, global trials)

**Data Requirements**: Trials (US/China/EU), regulatory guidance, financial (trial costs), epidemiology (6-8 skills)

**Expected Output**: 4000-6000 word report covering geographic trial distribution analysis, regulatory harmonization assessment (FDA/EMA/NMPA), trial cost comparison, enrollment feasibility, and strategic recommendations for global development optimization

**Capabilities Tested**: All 12 capabilities (comprehensive)

---

### Query L4.5: Precision Oncology Diagnostic-Therapeutic Co-Development Strategy

**User Input**:
```
@agent-competitive-landscape-analyst "Analyze the precision oncology landscape with focus on biomarker-drug co-development strategies. Evaluate successful companion diagnostic partnerships, regulatory pathways, market access implications, and recommend optimal biomarker development strategies."
```

**Agent Invocation**: Explicit (`@agent-competitive-landscape-analyst`)
**Expected Agent**: competitive-landscape-analyst (strategic)

**Complexity**: Strategic Synthesis (Biomarker-drug co-development)

**Data Requirements**: Targets, trials, FDA, publications, CMS, partnerships (6-8 skills)

**Expected Output**: 4000-6000 word report covering biomarker landscape, approved companion diagnostics, partnership models (pharma-diagnostics), regulatory co-development pathways, reimbursement for biomarker-guided therapy, and strategic recommendations for biomarker development programs

**Capabilities Tested**: All 12 capabilities (comprehensive)

---

## Test Execution Guidelines

### Phase 1: Level 1 Testing (Basic Queries)
**Purpose**: Validate core functionality with minimal complexity

1. Execute all 6 Level 1 queries sequentially
2. Verify data collection (1-2 skills per query)
3. Confirm analysis output (1000-1500 words)
4. Validate agent invocation pattern
5. Check report structure and quality

**Success Criteria**:
- All queries complete in 5-10 minutes
- Data collection transparent and accurate
- Analysis focused and insightful
- No errors in skill execution
- User receives clear, actionable summary

---

### Phase 2: Level 2 Testing (Intermediate Queries)
**Purpose**: Test multi-source synthesis and deeper analysis

1. Execute all 6 Level 2 queries sequentially
2. Verify multi-source data collection (2-4 skills per query)
3. Confirm analysis depth (2000-3000 words)
4. Validate competitive positioning analysis
5. Check strategic recommendation quality

**Success Criteria**:
- All queries complete in 10-20 minutes
- Multiple data sources integrated coherently
- Competitive positioning clear
- Strategic recommendations actionable
- Financial analysis included where relevant

---

### Phase 3: Level 3 Testing (Advanced Queries)
**Purpose**: Test complex multi-domain analysis and deep intelligence

1. Execute all 6 Level 3 queries sequentially
2. Verify complex data orchestration (4-6 skills per query)
3. Confirm comprehensive analysis (3000-5000 words)
4. Validate patent/IP landscape integration
5. Check partnership intelligence depth
6. Verify risk assessment thoroughness

**Success Criteria**:
- All queries complete in 20-40 minutes
- Advanced analysis frameworks applied
- Patent landscape integrated
- Partnership opportunities identified
- Risk assessment comprehensive
- Financial modeling included

---

### Phase 4: Level 4 Testing (Strategic Synthesis)
**Purpose**: Test full competitive landscape capabilities with board-ready reports

1. Execute all 5 Level 4 queries sequentially
2. Verify comprehensive data collection (6+ skills per query)
3. Confirm strategic report quality (4000-6000 words)
4. Validate multi-domain synthesis
5. Check all 12 capability areas tested
6. Verify report persistence to `reports/competitive-landscape/`

**Success Criteria**:
- All queries complete in 40-60 minutes
- Comprehensive multi-domain synthesis
- Board-ready report quality
- All 12 capabilities demonstrated
- Strategic recommendations clear and actionable
- Reports saved with proper YAML frontmatter
- Version controlled via git

---

## Capability Coverage Validation

### After completing all test phases, validate each capability area:

**1. Pipeline Intelligence & Tracking**:
- [ ] Multiple therapeutic area assessments
- [ ] Phase distribution analysis
- [ ] Development timeline predictions
- [ ] Attrition analysis

**2. Clinical Trial Monitoring & Analysis**:
- [ ] Trial design comparison
- [ ] Enrollment tracking
- [ ] Endpoint analysis
- [ ] Geographic strategy assessment

**3. Financial & Investment Analysis**:
- [ ] Stock performance analysis
- [ ] Deal valuation benchmarking
- [ ] Revenue forecasting
- [ ] R&D spending assessment

**4. Strategic Intelligence Synthesis**:
- [ ] Multi-source data integration
- [ ] Competitive positioning matrices
- [ ] SWOT analysis
- [ ] Strategic recommendations

**5. Data Collection & Source Management**:
- [ ] 8+ MCP servers utilized
- [ ] Data quality validation
- [ ] Source attribution
- [ ] Methodology transparency

**6. Analytical Frameworks & Modeling**:
- [ ] Competitive positioning matrices
- [ ] Pipeline overlap analysis
- [ ] Time-to-market modeling
- [ ] Market share forecasting

**7. Reporting & Communication**:
- [ ] Executive summaries
- [ ] Structured analysis sections
- [ ] Visual data presentation (tables, metrics)
- [ ] Actionable recommendations

**8. Technology & Automation Tools**:
- [ ] Skills library utilization
- [ ] Strategy system (REUSE/ADAPT/CREATE)
- [ ] Automated data collection
- [ ] Health check validation

**9. Therapeutic Area Specialization**:
- [ ] Oncology expertise
- [ ] Metabolic disease expertise
- [ ] Neurology expertise
- [ ] Cell & gene therapy expertise

**10. Partnership & Deal Intelligence**:
- [ ] M&A analysis
- [ ] Licensing landscape
- [ ] Collaboration patterns
- [ ] Deal structure analysis

**11. Risk Assessment & Early Warning**:
- [ ] Clinical risk identification
- [ ] Regulatory risk assessment
- [ ] Competitive threat analysis
- [ ] Patent cliff warnings

**12. Action Planning & Recommendations**:
- [ ] Prioritized recommendations
- [ ] Timeline considerations
- [ ] Resource allocation guidance
- [ ] Success criteria definition

---

## Summary Statistics

**Total Test Queries**: 40+

**Distribution by Level**:
- Level 1 (Basic): 6 queries
- Level 2 (Intermediate): 6 queries
- Level 3 (Advanced): 6 queries
- Level 4 (Strategic Synthesis): 5 queries

**Distribution by Therapeutic Area**:
- Obesity/Metabolic: 8 queries
- Oncology: 12 queries
- Neurology/Alzheimer's: 4 queries
- Cell & Gene Therapy: 6 queries
- Rare Disease: 3 queries
- Multi-therapeutic/Strategic: 7 queries

**Distribution by Capability Focus**:
- Pipeline & Clinical Trial Monitoring: 35+ queries
- Financial & Investment Analysis: 25+ queries
- Patent & IP Landscape: 8 queries
- Partnership & Deal Intelligence: 12 queries
- Risk Assessment: 30+ queries
- Strategic Recommendations: 40+ queries (all)

**Data Source Coverage**:
- ClinicalTrials.gov (ct_gov_mcp): 35+ queries
- FDA (fda_mcp): 30+ queries
- Financial (financials_mcp): 20+ queries
- SEC Edgar (sec_edgar_mcp): 10+ queries
- PubMed (pubmed_mcp): 15+ queries
- USPTO Patents (uspto_patents_mcp): 10+ queries
- Open Targets (opentargets_mcp): 8 queries
- CMS Healthcare (healthcare_mcp): 8 queries
- PubChem (pubchem_mcp): 4 queries

**Expected Total Test Runtime**: 10-20 hours (all 40+ queries)

**Expected Skills Created**: 30-50 new skills (depending on existing library)

**Expected Reports Generated**: 23 reports (all queries generate summaries, Level 3-4 generate full reports)

---

## Conclusion

This comprehensive test suite systematically validates all 12 capability areas of the competitive-landscape-analyst agent through 40+ queries grounded in current pharmaceutical news and trends. The progression from basic single-focus queries to complex strategic synthesis ensures thorough testing of:

✅ **Data orchestration**: Metadata-driven skill discovery and execution
✅ **Multi-domain synthesis**: Integration across 8+ MCP servers
✅ **Strategic analysis**: Competitive positioning, risk assessment, recommendations
✅ **Report quality**: Board-ready deliverables with proper persistence
✅ **Capability coverage**: All 12 core capabilities tested comprehensively

Successful execution demonstrates the platform's readiness for production pharmaceutical competitive intelligence use cases, from quick tactical assessments to comprehensive strategic landscape reports.
